

# United States Senate

COMMITTEE ON FINANCE

WASHINGTON, D.C. 20510-6224

April 21, 2010

## Via Electronic Transmission

Jennifer H. Vermeer  
Medicaid Director  
Iowa Medicaid Enterprise  
State of Iowa  
1305 East Walnut  
Des Moines, IA 50319

Dear Medicaid Director Vermeer:

In the United States, the federal and state governments spend roughly \$317 billion every year on the Medicaid program. As Ranking Member of the Senate Committee on Finance, I have an obligation to ensure that taxpayer dollars are appropriately spent on federal health care programs. Like the Medicare program, Medicaid suffers from systemic weaknesses that lead to fraud, waste, and abuse across the program, resulting in higher costs and less health care to those who are in need. The overutilization of prescription drugs, whether through drug abuse or outright fraud, plays a significant role in the rising cost of our healthcare system. The purpose of this letter is to request information regarding certain outliers in Iowa's Medicaid program and what steps Iowa takes to monitor rates of utilization.

In recent inquiries, I have asked the U.S. Department of Health and Human Services about physicians prescribing mental health drugs at astonishingly high rates. In addition to these concerns, a recent CNN report detailed the increasing abuse of OxyContin, Roxicodone, and Xanax. Specifically, the report described the role some pain management clinics and physicians play in the black market for these drugs. I write today to better ascertain how high rates of both mental health and pain medication utilization are affecting the Medicaid program, as well as how Iowa's rates compare to the national rates.

To that end, please provide charts that list of the top ten Medicaid prescribers of the following drugs for the years 2008 and 2009. For each prescriber, please provide his/her prescriber identifier, and the number of prescriptions written per drug per year, and the total amount billed to Medicaid per drug, separated for each year.

- Abilify;
- Geodon;
- Seroquel;
- Zyprexa;
- Risperdal;

- OxyContin;
- Roxicodone; and
- Xanax.

I thank you in advance for your cooperation and request that you provide the requested documents and written responses by no later than May 5, 2010. In your reply, please format information into a chart like the examples provided below. All formal correspondence should be sent electronically in PDF format to [Brian\\_Downey@finance-rep.senate.gov](mailto:Brian_Downey@finance-rep.senate.gov) or via facsimile to (202) 228-2131. Of course should you wish to discuss this matter further, please do not hesitate to contact Christopher Armstrong of my Committee staff at (202) 224-4515.

Sincerely,

A handwritten signature in cursive script, reading "Chuck Grassley".

Charles E. Grassley  
Ranking Member

Attachment

**Drug X, 2008**

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000

**Drug X, 2009**

Prescriber Identifier	Total prescriptions	Total billed to Medicaid
123456789	25,000	250,000
234567891	24,000	240,000
345678912	23,000	230,000
456789123	22,000	220,000
567891234	21,000	210,000
678912345	20,000	200,000
789123456	19,000	190,000
891234567	18,000	180,000
912345678	17,000	170,000
012345678	16,000	160,000



# STATE OF IOWA

CHESTER J. CULVER, GOVERNOR  
PATTY JUDGE, LT. GOVERNOR

MAY 4 2010

DEPARTMENT OF HUMAN SERVICES  
CHARLES J. KROGMEIER, DIRECTOR

The Honorable Charles E. Grassley  
United States Senator  
135 Hart Senate Office Building  
Washington, D.C. 20510-1501

Attn: Brian Downey

Re: Iowa Medicaid Providers/2008-2009

Dear Senator Grassley:

I am in receipt of your April 21, 2010 letter which requested information on the top ten Medicaid prescribers of select mental health and pain medications for 2008 and 2009. The letter also requests information regarding steps Iowa takes to monitor rates of utilization and to curb fraud, waste and abuse.

Attached please find the data for calendar years 2008 and 2009 as requested in your letter. Iowa has included the following:

- The average monthly Medicaid eligibles for the calendar year,
- The total number of prescriptions,
- The number of total prescriptions that were brand,
- The number of total prescriptions that were generic,
- The unique number of Medicaid members receiving the prescriptions, and
- The total amount Medicaid reimbursed for the total number of prescriptions.

One important issue the data does not take into consideration is the percent of Medicaid patients the particular prescriber sees in comparison to the other prescribers. If the prescriber is primarily dedicated to Medicaid the utilization data may be skewed in comparison to the other prescribers in the data pull who see a lower percentage of Medicaid patients.

The Iowa Medicaid program utilizes a variety of mechanisms to monitor utilization within the program and has implemented several processes to curtail fraud, waste and abuse as detailed below.

1) Monitor Utilization

- a) *Monthly Claims Reports* - include top prescribers by utilization and dollar amount to identify outliers.
- b) *Drug Utilization Review Commission (DUR)* - is a federally mandated quality assurance body that performs a quality review of covered outpatient drugs that assures that prescriptions are appropriate, medically necessary, and not likely to result in adverse medical outcomes. Focused studies and individual profile review with follow-up letters to individual prescribers are examples of activities used to monitor the benefit and identify outliers.
- c) *DUR Mental Health Advisory Group* - is composed of Medicaid healthcare practitioners including psychiatrists, a pediatrician and a pharmacist, who meet ongoing to review mental health clinical issues referred by the DUR and provide recommendations back to them.
- d) *DUR Quarterly Narcotics Reports to Prescribers* - This report is provided to prescribers on a quarterly basis and highlights patients using narcotics prescribed by multiple providers and/or filled at multiple pharmacies.

# Iowa Medicaid Top 10 Prescribers for CY 2008 and 2009

CY 2008 : Average Monthly Eligibles 335,350

<b>ABILIFY</b>	<b>2008</b>
----------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1841220290	591	591	0	120	\$195,563.56
1285681528	577	577	0	99	\$185,722.17
1861562555	444	444	0	105	\$145,828.92
1215964796	405	405	0	72	\$115,864.48
1508946088	359	359	0	68	\$118,259.67
1821196700	329	329	0	61	\$103,079.71
1073500690	322	322	0	63	\$106,323.74
1699850305	320	320	0	47	\$85,735.71
0074575	294	294	0	97	\$108,137.19
1851383616	293	293	0	48	\$148,419.77

<b>GEODON</b>	<b>2008</b>
---------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1952333437	284	284	0	70	\$66,242.42
1699850305	277	277	0	28	\$38,862.48
1215964796	274	274	0	39	\$41,655.25
1538173778	195	195	0	21	\$65,351.86
0040246	165	165	0	49	\$41,826.28
1851383616	157	157	0	23	\$66,838.85
1376586800	149	149	0	25	\$39,265.22
1285681528	134	134	0	21	\$38,911.67
1407806128	113	113	0	17	\$30,551.02
1033157557	111	111	0	25	\$37,526.56

<b>SEROQUEL</b>	<b>2008</b>
-----------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1538173778	816	816	0	145	\$212,270.01
1023002508	611	611	0	104	\$112,242.31
1285681528	462	462	0	63	\$121,016.44
0040246	454	454	0	156	\$108,105.48
1700806262	383	383	0	81	\$40,591.12
1407806128	376	376	0	54	\$87,091.04
1871586578	353	353	0	69	\$72,781.13
1851383616	341	341	0	53	\$93,849.26
1356564371	329	329	0	73	\$83,452.88
1730239732	318	318	0	71	\$52,557.94

<b>ZYPREXA</b>	<b>2008</b>
----------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861559486	197	197	0	51	\$55,911.82
1225128127	133	133	0	10	\$70,864.68
1396709457	118	118	0	24	\$35,574.23
1023002508	111	111	0	10	\$39,951.94
0040246	105	105	0	35	\$52,730.09
1356564371	91	91	0	18	\$48,397.64
1043211303	86	86	0	14	\$56,445.05
1851383616	85	85	0	8	\$54,798.71
1982605762	85	85	0	14	\$29,843.10
1730239732	77	77	0	22	\$27,160.99

**RISPERDAL****2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1376586800	1,146	1,101	45	219	\$241,810.07
1568424208	715	706	9	93	\$97,531.33
1043284169	670	622	48	160	\$130,149.22
1457315285	659	601	58	124	\$122,909.33
0040246	641	641	0	224	\$143,049.55
1841220290	560	521	39	128	\$121,001.03
1407806128	514	498	16	91	\$94,197.87
1861559486	506	488	18	117	\$94,273.41
1861562555	504	491	13	128	\$95,316.36
1508946088	448	435	13	79	\$100,045.87

**OXYCONTIN****2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1104804053	146	17	129	24	\$18,079.61
0040246	145	14	131	53	\$21,828.81
1952479024	119	56	63	38	\$20,714.38
1376538488	117	61	56	23	\$34,516.28
1215934914	104	9	95	45	\$12,338.25
1679688626	94	18	76	11	\$17,467.10
1144290313	88	8	80	8	\$20,503.59
1386639516	73	6	67	34	\$10,829.51
1477540011	67	5	62	33	\$6,663.26
1982608741	65	53	12	8	\$10,152.16

**ROXICODONE****2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
0040246	136	5	131	47	\$14,461.76
1104804053	129	0	129	20	\$12,949.91
1215934914	96	1	95	41	\$9,703.90
1144290313	85	5	80	7	\$11,077.68
1679688626	76	0	76	7	\$8,276.02
1386639516	67	0	67	31	\$7,575.84
1376538488	65	9	56	15	\$6,630.67
1952479024	64	1	63	24	\$4,669.54
1477540011	62	0	62	30	\$5,442.86
1710921119	52	2	50	9	\$3,812.76

**XANAX****2008**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1285681528	573	0	573	85	\$6,448.24
0040246	452	4	448	189	\$5,080.71
1154379972	429	0	429	64	\$5,135.93
1356564371	383	0	383	77	\$3,914.04
1043211303	350	0	350	54	\$3,432.50
1396709457	331	0	331	50	\$3,210.83
1417964875	325	0	325	72	\$4,302.75
1538173778	319	2	317	50	\$3,900.64
1265411078	311	0	311	45	\$2,793.25
1407806128	310	0	310	58	\$3,037.50

**ABILIFY 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861562555	844	844	0	133	\$281,852.93
1215964796	803	803	0	92	\$183,043.09
1841220290	801	801	0	127	\$299,268.10
1285681528	743	743	0	130	\$247,307.97
1699850305	625	625	0	51	\$113,151.61
1508946088	493	493	0	78	\$164,440.62
1821196700	438	438	0	68	\$147,343.09
1407806128	435	435	0	74	\$169,158.95
1073500690	404	404	0	75	\$144,978.43
1982787727	393	393	0	71	\$173,978.68

**GEODON 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215964796	768	768	0	73	\$107,689.82
1952333437	530	530	0	93	\$128,290.60
1699850305	323	323	0	28	\$33,101.29
1538173778	247	247	0	27	\$91,628.46
1285681528	237	237	0	38	\$61,586.87
1003867888	198	198	0	17	\$47,371.79
1376586800	184	184	0	23	\$48,847.27
1407806128	170	170	0	18	\$57,830.36
1598765877	165	165	0	16	\$45,595.62
1033157557	163	163	0	28	\$52,949.92

**SEROQUEL 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1538173778	851	851	0	127	\$269,474.50
1023002508	780	780	0	106	\$180,155.37
1730239732	599	599	0	87	\$136,541.82
1356564371	518	518	0	83	\$144,756.41
1285681528	513	513	0	89	\$191,223.08
1407806128	477	477	0	61	\$127,897.10
1619099884	438	438	0	67	\$133,240.11
1699850305	417	417	0	31	\$41,221.60
1710915392	405	405	0	59	\$146,981.79
1982605762	376	376	0	79	\$89,422.33

**ZYPREXA 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861559486	308	308	0	61	\$99,384.77
1730239732	282	282	0	76	\$80,194.94
1023002508	172	172	0	14	\$71,611.06
1043211303	138	138	0	23	\$93,518.67
1538173778	128	128	0	16	\$104,249.86
1356564371	121	121	0	20	\$67,529.49
1841220290	112	112	0	15	\$54,703.57
1225097843	110	110	0	12	\$66,931.53
1699850305	105	105	0	12	\$16,517.35
1013964279	104	104	0	9	\$47,236.09

**RISPERDAL 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1376586800	1,358	590	768	381	\$202,778.27
1457315285	1,160	422	738	196	\$140,463.51
1841220290	901	284	617	194	\$119,934.05
1568424208	896	278	618	114	\$67,568.41
1215964796	862	205	657	120	\$55,766.22
1043284169	853	314	539	208	\$106,374.18
1407806128	817	253	564	179	\$93,356.01
1861562555	776	250	526	193	\$73,940.63
1285681528	718	258	460	143	\$86,998.18
1861559486	704	187	517	164	\$72,668.19

**OXYCONTIN 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215934914	201	47	154	44	\$32,959.13
1376538488	181	109	72	23	\$64,698.58
1952479024	85	24	61	22	\$11,643.60
1144290313	85	7	78	7	\$14,738.16
1134191018	74	13	61	7	\$7,587.05
1679688626	74	53	21	7	\$25,447.12
1811975469	68	13	55	11	\$39,653.72
1487680195	67	46	21	17	\$15,588.91
1972653962	67	22	45	7	\$16,028.32
1386757706	64	28	36	12	\$18,000.21
1063437812	64	1	63	6	\$652.03
1568570398	64	27	37	7	\$16,709.52

**ROXICODONE 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215934914	156	2	154	36	\$15,695.31
1376538488	85	13	72	15	\$3,338.79
1144290313	78	0	78	5	\$10,312.86
1063437812	63	0	63	5	\$568.83
1952479024	63	2	61	18	\$3,190.56
1134191018	61	0	61	6	\$2,472.28
1124020615	56	0	56	8	\$1,288.71
1811975469	55	0	55	9	\$5,259.13
1184697435	55	0	55	8	\$3,385.68
1730197476	54	0	54	12	\$7,865.25
1437176005	54	12	42	7	\$5,270.50

**XANAX 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1285681528	915	0	915	96	\$10,011.70
1356564371	760	0	760	104	\$7,424.15
1154379972	657	0	657	81	\$7,400.49
1043211303	577	0	577	64	\$5,266.37
1518913540	554	67	487	64	\$9,261.15
1417964875	463	0	463	75	\$5,317.49
1407806128	448	0	448	61	\$4,032.49
1033389226	392	0	392	69	\$4,624.23
1265411078	390	0	390	50	\$3,487.88
1407906407	365	0	365	46	\$3,629.15



PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN  
DIANNE FEINSTEIN, CALIFORNIA  
CHARLES E. SCHUMER, NEW YORK  
RICHARD J. DURBIN, ILLINOIS  
SHELDON WHITEHOUSE, RHODE ISLAND  
AMY KLOBUCHAR, MINNESOTA  
AL FRANKEN, MINNESOTA  
CHRISTOPHER A. COONS, DELAWARE  
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA  
ORRIN G. HATCH, UTAH  
JON KYL, ARIZONA  
JEFF SESSIONS, ALABAMA  
LINDSEY O. GRAHAM, SOUTH CAROLINA  
JOHN CORNYN, TEXAS  
MICHAEL S. LEE, UTAH  
TOM COBURN, OKLAHOMA

**United States Senate**

COMMITTEE ON THE JUDICIARY

WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*  
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

January 23, 2012

**VIA ELECTRONIC TRANSMISSION**

Jennifer Vermeer  
Medicaid Director  
1305 Walnut Street  
Des Moines, IA 50319

Dear Director Vermeer,

In 2009, the Department of Human Services provided my staff with data regarding the top ten prescribers of several pain management and mental health drugs in Iowa. These types of drugs have addictive properties, and the potential for fraud and abuse by prescribers and patients is extremely high. Mental health drugs continue to be prescribed at astounding rates and pain management clinics are turning into a hotbed for black market painkillers. When these drugs are prescribed to Medicaid patients, it is the American people who pay the price for over-prescription, abuse, and fraud.

After an extensive review of prescribing habits of the serial prescribers of pain and mental health drugs in Iowa, I have concerns about the oversight and enforcement of Medicaid abuse in Iowa. While I am sensitive to concerns about the potential for misinterpretation of the data you provided, the numbers themselves are quite shocking.

For example, the top prescriber of Risperdal wrote 1,358 prescriptions for the drug in 2009 for a total of 381 unique members. The next top prescriber wrote prescriptions for only 196 unique members. This outlier is consistent with many of the requested drugs—with the top prescribers writing double or triples the number of prescriptions as the other prescribers on the list.

It is my intention to ensure that each of the states is adequately monitoring, investigating, and stopping fraud and over-prescription of these types of drugs. Therefore, please provide answers to the following questions:

1. What action, if any, has your agency taken with respect to the prescribers identified to the Committee?
2. If there has been no action taken with respect to these prescribers, please explain why not.
3. Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.
4. Please provide the 2010 and 2011 numbers for the top prescribers of these same drugs.
5. Has each of these prescribers been cross-checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?
6. Have any of the prescribers identified to this Committee been referred to Iowa's medical board?
7. Is there any system set up in your state to identify and monitor excessive prescription writing? If not, why not?
8. Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?
9. Does Iowa maintain a database of all prescribed controlled-substances? If so, what entities have access to it?
10. Does Iowa have any point-of-sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?
11. Were any of these top ten prescribers identified in the federal-mandated Drug Utilization Review or CMS-base retrospective reviews?
12. Does Iowa have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?

Thank you in advance for your cooperation and attention in this matter. When responding to this letter, please number your answers in accordance with my questions. I would appreciate a response by February 13, 2012. If you have any questions, please do not hesitate to contact Erika Smith of my staff at (202) 224-5225.

Sincerely,

A handwritten signature in blue ink that reads "Chuck Grassley". The signature is written in a cursive, flowing style.

Charles E. Grassley  
Ranking Member  
Committee on the Judiciary



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

February 9, 2012

## VIA ELECTRONIC TRANSMISSION

The Honorable Senator Grassley  
United States Senator  
Ranking Member  
Committee on the Judiciary  
Washington, D.C. 20510-6200

Attn: Erika Smith

Re: Iowa Medicaid Providers

Dear Senator Grassley:

This is in response to your recent inquiry of Medicaid Director Jennifer Vermeer. The request is for additional data on the top ten Medicaid prescribers of select mental health and pain medications for calendar years 2010 and 2011, and to provide responses to questions on prior data submitted at your request. Data was provided, as requested, for calendar years 2008 and 2009 in April 2010, which also included information on how Iowa Medicaid monitors drug utilization.

A. Data: Attached please find the requested data for calendar years 2010 and 2011. Iowa has included the same data fields as on the prior submission including:

- The average monthly Medicaid eligibles for the calendar year,
- The total number of prescriptions,
- The number of total prescriptions that were brand,
- The number of total prescriptions that were generic,
- The unique number of Medicaid members receiving the prescriptions, and
- The total amount Medicaid reimbursed for the total number of prescriptions.

This is a very limited set of data, which does not take into account many factors that could result in misinterpretation of the data. Here are just some, but not all, of the factors the data does not take into consideration:

- Many of the drugs used for mental health have high discontinuation rates due to high side effect profiles and/or the need for frequent dose adjustments. This could result in multiple prescriptions for the same drug but different strengths, taken concurrently to get to a specific dose. There could also be multiple prescriptions for different drugs in the same therapeutic category due to switching.

- All of the drugs for which information was requested, with the exception of OxyContin® and Roxicodone™, can have prescriptions written to include refills. Additionally the prescriber can telephone in refills to the pharmacy. Each prescription does not necessitate the prescriber seeing the patient and/or writing a new prescription. While OxyContin® and Roxicodone™ prescriptions cannot have refills; a prescriber may issue multiple prescriptions to the patient at one visit.
- Prescriber patient population is an important factor in that if they have a high percentage of patients where abuse is a concern, they may write prescriptions in smaller quantities to keep utilization in check. For example, rather than providing a thirty day supply of the drug, the prescriber may only provide a seven or fourteen day supply. This may result in more prescriptions for that prescriber, but this is not necessarily inappropriate.
- The percent of Medicaid patients the particular prescriber sees in comparison to the other prescribers. For example, if the prescriber is primarily dedicated to Medicaid the utilization data may be skewed in comparison to the other prescribers in the data pull who see a lower percentage of Medicaid patients. Additionally the percent of the practice dedicated to children and adolescents versus adults, as Medicaid is heavily weighted with children and adolescents. Also the area of practice or specialty could also impact the data.
- The ratio of medication in question by the prescriber as compared to overall medications prescribed in the same class.
- The ratio of patients prescribed a specific medication versus the total number of patients seen.
- The number of nonenrolled prescribers utilizing the supervising physician identifier. For example, physician assistants are not enrolled providers with Iowa Medicaid. If the prescription is for a drug that requires prior authorization it must be submitted and approved under the supervising physician identifier. The prescription would indicate that physician's identifier, but technically the physician assistant is seeing the patient.
- If the prescriber is a "facility" practitioner. Some prescribers are responsible for all patients in a particular facility, which may be all Medicaid and the number may seem artificially high in comparison to practitioners in a private setting. Additionally, certain facilities may be subject to a formulary, and prescribers may therefore selectively prescribe only certain drugs in a category.
- There is a pretty wide disparity in the number of psychiatric providers in Iowa compared to other medical providers, and many of them are unwilling to treat Medicaid members or may limit the number of Medicaid members they provide service to.

Your letter voices concern that the requested drug data shows many of the top prescribers write double or triple the number of prescriptions as the other prescribers on the list. Again, many of the factors above may influence the data and the Medicaid program is not privy to all the specifics indicated above.

- B. Prescription Drug Oversight: The Iowa Medicaid program utilizes a variety of mechanisms to monitor utilization within the program and has implemented several processes to curtail fraud, waste and abuse. These processes were identified in the document previously sent. This document includes all processes, including any updates since the prior communication in 2010.
- i) Monitor Utilization
- (1) Monthly Claims Reports - include top prescribers by utilization and dollar amount to identify outliers.
  - (2) Drug Utilization Review (DUR) Commission - is a federally mandated quality assurance body that performs a quality review of covered outpatient drugs that assures that prescriptions are appropriate, medically necessary, and not likely to result in adverse medical outcomes. Focused studies and individual profile review with follow-up letters to individual prescribers are examples of activities used to monitor the benefit and identify outliers.
  - (3) DUR Mental Health Advisory Group- is composed of Medicaid healthcare practitioners including psychiatrists, a pediatrician and a pharmacist, who meet ongoing to review mental health clinical issues referred by the DUR and provide recommendations back to them.
  - (4) DUR Quarterly Narcotics Reports to Prescribers - This report is provided to prescribers on a quarterly basis and highlights patients using narcotics prescribed by multiple providers and/or filled at multiple pharmacies.
  - (5) Lock-In Program - the goal is to promote quality health care for Medicaid members by preventing harmful practices including duplication of scheduled and non-scheduled medications, unintended medication interactions, duplication of medical services and treatments and medication abuse. The program also assists the member in establishing care with one physician who can oversee and coordinate all health care needs. Members can be referred to the Lock-In program from various sources. In addition to referrals, an algorithm runs monthly that looks at how many prescriptions a member is receiving, the reason they are taking the prescription and if they are on long- and/or short-acting narcotics. Included in the algorithm is the number of prescribers, their locations, and the number of office visits and non-emergent emergency room visits. If, during our review, we find overutilization in any of the above areas a member is placed in Lock-In and assigned to one pharmacy, one primary care physician and one hospital for 24 months. If any suspicious prescribing patterns are noticed while reviewing the member for over utilization, we refer the provider to the Program Integrity Unit for further review. The Program Integrity Unit reviews our referral and may refer the provider to the Iowa Board of Medicine.

The review also looks at psychotropic utilization. The program also sends the Iowa Plan for Behavioral Health a data pull of all Foster Care children who

appear to be prescribed higher than normal amounts of psychotropic medications and request they perform a review on the data provided.

- (6) Program Integrity (PI) - this unit will routinely inspect claims submitted to the Iowa Medicaid Enterprise (IME) to assure that Medicaid is paying appropriately for covered services. This unit also does targeted reviews based on reported or suspected issues. Aberrant providers are referred to the Medicaid Fraud Control Unit (MFCU) within the Iowa Department of Inspections and Appeals and the Iowa Board of Medicine for further investigation.
  - (7) Iowa Plan for Behavioral Health-accesses pharmacy data during case specific reviews for managed services. Discussions with providers ensue regarding the number of psychotropics utilized, number of psychotropic classes, treatment adherence and treatment duration. Pursuit of the least number of psychotropics to address the patient's needs is the goal. Further, specific case review has unveiled questionable prescription procurement implicating potential abuse and/or diversion whereupon providers are notified of the information for direct intervention with the patient(s)
  - (8) Integrated Health Homes for the Seriously Mentally Ill-have been initiated with enhanced scrutiny and coordinated management of patients medical and behavioral health needs including pharmacotherapy. The anticipated expansion will address an ever increasing number of patients for optimization of treatment interventions yielding a decreasing number of potentially overused and/or abused medications.
- ii) Management Tools
- (1) Iowa Medicaid Electronic Record System (I-MERS) - is a web-based tool that will give providers up-to-date information about what services have been paid for by Iowa Medicaid. I-MERS will allow treating providers to view Medicaid members' medical procedures, prescriptions, and other services that are currently in the Medicaid computer system.
  - (2) Pharmacy Prior Authorization (PA) - means obtaining approval for a medication before the medication is provided to a member.
  - (3) Clinical PA – A clinical PA is required for several controlled substances including stimulants, short acting fentanyl products, narcotic nasal sprays, OxyContin®, sedative/hypnotics, and select brand name controlled substances. Specific clinical criteria must be met for these products and other medications to promote appropriate use.
  - (4) Preferred Drug List (PDL) PA – medications which are more costly and/or have a high potential for abuse or misuse are made nonpreferred on the PDL

resulting in a PA. Preferred medications must be tried in order for a nonpreferred medication to be considered.

- (5) Prospective Drug Utilization Review Edits - means a process in which a request for a medication for a particular member is screened for potential medication therapy problems before the product is dispensed. This includes quantity limits and refill tolerance, just to name a few, both of which limit overuse and promote cost effectiveness.
- (6) Iowa Prescription Monitoring Program (PMP) - the Iowa Board of Pharmacy has established an electronic prescription monitoring program for the purpose of compiling records of Schedule II, III, and IV Controlled Substances dispensed by Iowa pharmacies. The program is designed to provide information regarding the prescribing of controlled substances in order to determine appropriate prescribing and treatment for individual patients without fear of contributing to a patient's abuse or dependence on addictive medication or diversion of those medications to illicit use. Information collected by Iowa's PMP is "privileged and strictly confidential information," except that the Pharmacy Board may provide information from the PMP in the following instances:
  - (i) When pharmacists and prescribing practitioners request the information for purposes of providing care to a patient, or
  - (ii) When an individual requests their own program information, or
  - (iii) When presented with a court order, subpoena, or other means of legal compulsion for access to or release of program information that is issued based upon a determination of probable cause in the course of a specific investigation of a specific individual.
- (7) Iowa Prescription Abuse Reduction (PAR) Task Force- several Iowa Medicaid staff members participated in the task force convened by the Governor's Office of Drug Control Policy (ODCP). This was a multiagency task force which met in the fall of 2011 to help refine the nature and scope of drug abuse in Iowa and recommended steps to address it. This was not limited to Medicaid. Similar to the national plan released earlier this year, the Iowa Plan for reducing prescription abuse expands on the State's comprehensive Drug Control Strategy by offering a blueprint for action targeting four key areas: (1) Education & Intervention; (2) Secure Storage & Safe Disposal; (3) Monitoring and (4) Enforcement. The final report can be found at the following link: <http://www.iowa.gov/odcp/docs/Reducing%20Rx%20Abuse%20in%20Iowa%20Strategy%201-5-12.pdf>. The Medicaid program will continue to work with the various agencies involved, as well as internally, to enhance efforts associated with the four key areas listed.



C. Response to Questions

**1) What action, if any, has your agency taken with respect to the prescribers identified to the Committee?**

The prescribers were reviewed, prior to the submission of the data. In regards to controlled substances, we are aware some of these prescribers are being reviewed by the Iowa Board of Medicine. However, without all of the accompanying information as outlined in Item A. Data, it is difficult to determine if the prescribers of mental health medications are truly outliers in regards to their prescribing habits of these drugs.

**2) If there has been no action taken with respect to these prescribers, please explain why not.**

See response to question 1.

**3) Please identify which of the providers identified to the Committee remain eligible to bill the Medicaid Program.**

We have attached the top ten prescriber lists for each year requested, 2008-2011. Any prescriber ID marked with an asterisk is no longer eligible to bill Iowa Medicaid as an individual.

**4) Please provide the 2010 and 2011 numbers for the top prescribers of these same drugs.**

The attachment provided with this letter has calendar year 2010 and 2011 numbers for the top prescribers of these same drugs.

**5) Has each of these prescribers been cross-checked for complaints or misconduct with the state medical board or the National Practitioner Data Bank? If not, do you plan to do so?**

The number one prescriber in each drug category, for each calendar year was cross-checked with their corresponding state medical board for complaints. No publically posted issues were identified based on this review.

**6) Have any of the prescribers identified to this Committee been referred to Iowa's medical board?**

There are several prescribers, identified as Pain Specialists that the IME has referred to the Iowa Board of Medicine. In calendar year 2011, these are included in the top five prescribers of OxyContin® and the number one prescriber of Roxicodone™. Additionally, the number seven prescriber of Xanax® has also been referred to the Board. The calendar year 2010 data includes as the number six prescriber of OxyContin® and the number ten prescriber of Xanax®, a physician who is currently under investigation by the Iowa Board of Medicine, being prosecuted by the Attorney General's office.

**7) Is there any system set up in your state to identify and monitor excessive prescription writing? If not, why not?**

Iowa Medicaid is not aware of a specific "system" to monitor excessive prescription writing. The Board of Pharmacy operates the Iowa Prescription Monitoring Program

(PMP) described earlier and the Iowa Board of Medicine is responsible for monitoring activities of its licensees. The Iowa Board of Medicine recently adopted rules requiring all licensed physicians in the State of Iowa to complete continuing medical education on chronic pain medication management. In addition to offering the newly required physician training via an online webinar, the Iowa Board of Medicine is also supporting the chronic pain management education requirement by offering a free book—“Responsible Opioid Prescribing: A Physician’s Guide”—by Scott Fishman, M.D., a nationally recognized pain specialist. The book discusses the use of pain management agreements and prescription monitoring programs as tools for more safely prescribing narcotic drugs. The Board has also adopted rules to recommend physicians consider establishing pain management agreements, use drug screens, and review a patient’s controlled substance prescription history in the Iowa PMP database if the physician believes the patient is at risk of abuse or diversion of the medication. PMP issues will be addressed in greater detail in the Monitoring section of this report. Additionally, as mentioned previously, Iowa Medicaid is participating in the Iowa Prescription Abuse Reduction (PAR) Task Force which is a multi-agency task force with the purpose of reducing prescription abuse in Iowa.

Additionally, the Program Integrity Unit within the IME regularly corresponds with investigators from both the MFCU and Iowa Board of Medicine regarding physicians that have apparent prescription pattern abnormalities. Support for these communications come from review efforts from Lock-In and from data analytics run on claims history. Results of these investigations have resulted in physician sanction, loss of hospital privileges and/or physicians voluntarily giving up their Drug Enforcement Administration (DEA) prescriber number.

**8) Have you received any training or guidance from the Centers for Medicare and Medicaid Studies to help identify potential issues with prescription drugs?**

No. There is a significant problem regarding controlled substances in the Medicaid program. The Omnibus Budget Reconciliation Act (OBRA) of 1990, which established the drug rebate program at section 1927 of the Social Security Act, requires, with a few limited statutory exceptions, that a State that chooses to include outpatient drugs within its Medicaid program must cover, for their medically accepted indications, all FDA approved prescription drugs of manufacturers that have entered into drug rebate agreements. This results in requiring programs to cover brand name controlled substances (when a generic product is available). While prior authorization requirements can be put in place, those patients who really want the brand name can eventually find their way to the brand name. If the generic medication does not work, they should be trying a different medication, not the brand. However this does not preclude the generic from abuse and or diversion, but the brand is more costly to the program. In general this additional cost would apply to other categories of drugs where the member receives a brand when there is a generic, or several different generics available in that therapeutic class. An additional expense is the requirement to cover all FDA approved prescription drugs of manufacturers that have entered into drug rebate agreements. Many new drugs are not therapeutically superior to existing drugs,

they may just be new strengths or salt forms, and there may already be more cost effective generic drugs in that therapeutic category.

**9) Does Iowa maintain a database of all prescribed controlled-substances? If so, what entities have access to it?**

The Iowa Board of Pharmacy has established an electronic prescription monitoring program (PMP) for the purpose of compiling records of Schedule II, III, and IV Controlled Substances dispensed by Iowa pharmacies. Authorized health care practitioners (prescribers and pharmacists) are able to access PMP information regarding their patient's use of controlled substances to assist them in determining appropriate treatment options and to improve the quality of patient care. There is legislation pending that would give the IME access to the PMP database.

**10) Does Iowa have any point-of-sale restrictions related to maximum units, prior authorization, therapeutic duplication, or early refill? If not, why not?**

Yes Iowa Medicaid uses all the point-of-sale restrictions listed. However the program must operate within the Legislative limitations applied to the program. For example, Iowa Code language, which implemented a Preferred Drug List (PDL), excluded certain categories of drugs from inclusion such as drugs for mental health, human immunodeficiency virus or acquired immune deficiency syndrome, transplantation and cancer. The mental health drug exclusion has since been removed. But there is significant resistance from providers and advocacy organizations when any restrictions are placed on the mental health drugs.

**11) Were any of these top ten prescribers identified in the federal-mandated Drug Utilization Review or CMS-base retrospective reviews?**

While the prescribers identified in the top ten for pain medications and/or mental health drugs did not receive letters specific to their being a top prescriber, the prescribers identified have received DUR communications for duplicate therapy and/or overuse of the drugs listed in this data request. Additionally, the DUR Commission has looked at members using short-acting opioids for an extended period of time without a long-acting opioid and use of duplicate therapy with methadone and a long-acting opioid. Additionally, the DUR Commission has had numerous mental health drug initiatives which have also been reviewed to the Mental Health Advisory Group. These initiatives have included quantity limits, prior authorization criteria, removal of exclusion on the Preferred Drug List and usage in children. The group works in coordination with the Iowa Plan for Behavioral Health, which oversees the majority of mental health care for Iowa Medicaid.


**12) Does Iowa have any programs in place to educate providers about the prescription of antipsychotics to children and adolescents?**

OBRA'90 language requires DUR boards to conduct ongoing educational programs to educate practitioners about medication therapy problems, with the goal of improving prescribing and dispensing practices. Based on the findings, the DUR Commission in Iowa may suggest changes in prescribing or dispensing suggestions may be member-specific, drug-specific or both. As an additional educational initiative, the Commission

generates a quarterly newsletter, the DUR Digest, which is posted on the website practices, which may be conveyed by written, oral, electronic or face-to-face communication. These [www.iadur.org](http://www.iadur.org) and provided to all Iowa Medicaid prescribers and pharmacies.

Please feel free to contact me if you need additional information.

Sincerely,

A handwritten signature in black ink, appearing to read "JH Vermeer", with a long horizontal flourish extending to the right.

Jennifer H. Vermeer  
Director

JHV:slp

Attachment (1)

# Iowa Medicaid Top 10 Prescribers for CY 2008 and 2009

CY 2008 : Average Monthly Eligibles 335,350

## ABILIFY 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1841220290	591	591	0	120	\$195,563.56
1285681528	577	577	0	99	\$185,722.17
1861562555	444	444	0	105	\$145,828.92
1215964796	405	405	0	72	\$115,864.48
1508946088	359	359	0	68	\$118,259.67
1821196700	329	329	0	61	\$103,079.71
1073500690	322	322	0	63	\$106,323.74
1699850305	320	320	0	47	\$85,735.71
0074575 *	294	294	0	97	\$108,137.19
1851383616	293	293	0	48	\$148,419.77

## GEODON 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1952333437	284	284	0	70	\$66,242.42
1699850305	277	277	0	28	\$38,862.48
1215964796	274	274	0	39	\$41,855.25
1538173778	195	195	0	21	\$65,351.86
0040246 *	165	165	0	49	\$41,826.28
1851383616	157	157	0	23	\$66,838.85
1376586800	149	149	0	25	\$39,265.22
1285681528	134	134	0	21	\$38,911.67
1407806128	113	113	0	17	\$30,551.02
1033157557	111	111	0	25	\$37,526.56

## SEROQUEL 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1538173778	816	816	0	145	\$212,270.01
1023002508	611	611	0	104	\$112,242.31
1285681528	462	462	0	63	\$121,016.44
0040246 *	454	454	0	156	\$108,105.48
1700806262	383	383	0	81	\$40,591.12
1407806128	376	376	0	54	\$87,091.04
1871586578	353	353	0	69	\$72,781.13
1851383616	341	341	0	53	\$93,849.26
1356564371	329	329	0	73	\$83,452.88
1730239732	318	318	0	71	\$52,557.94

## ZYPREXA 2008

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861559486	197	197	0	51	\$55,911.82
1225128127	133	133	0	10	\$70,864.68
1396709457	118	118	0	24	\$35,574.23
1023002508	111	111	0	10	\$39,951.94
0040246 *	105	105	0	35	\$52,730.09
1356564371	91	91	0	18	\$48,397.64
1043211303	86	86	0	14	\$56,445.05
1851383616	85	85	0	8	\$54,798.71
1982605762	85	85	0	14	\$29,843.10
1730239732	77	77	0	22	\$27,160.99

\* 2/2012 - not currently enrolled individually  
in Iowa Medicaid.

<b>RISPERDAL</b>	<b>2008</b>
------------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1376586800	1,146	1,101	45	219	\$241,810.07
1568424208	715	706	9	93	\$97,531.33
1043284169*	670	622	48	160	\$130,149.22
1457315285*	659	601	58	124	\$122,909.33
0040246 *	641	641	0	224	\$143,049.55
1841220290	560	521	39	128	\$121,001.03
1407806128	514	498	16	91	\$94,197.87
1861559486	506	488	18	117	\$94,273.41
1861562555	504	491	13	128	\$95,316.36
1508946088	448	435	13	79	\$100,045.87

<b>OXYCONTIN</b>	<b>2008</b>
------------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1104804053	146	17	129	24	\$18,079.61
0040246 *	145	14	131	53	\$21,828.81
1952479024*	119	56	63	38	\$20,714.38
1376538488	117	61	56	23	\$34,516.28
1215934914	104	9	95	45	\$12,338.25
1679688626	94	18	76	11	\$17,467.10
1144290313	88	8	80	8	\$20,503.59
1386639516	73	6	67	34	\$10,829.51
1477540011*	67	5	62	33	\$6,663.26
1982608741	65	53	12	8	\$10,152.16

<b>ROXICODONE</b>	<b>2008</b>
-------------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
0040246	136	5	131	47	\$14,461.76
1104804053	129	0	129	20	\$12,949.91
1215934914	96	1	95	41	\$9,703.90
1144290313	85	5	80	7	\$11,077.68
1679688626	76	0	76	7	\$8,276.02
1386639516	67	0	67	31	\$7,575.84
1376538488	65	9	56	15	\$6,630.67
1952479024*	64	1	63	24	\$4,669.54
1477540011*	62	0	62	30	\$5,442.86
1710921119	52	2	50	9	\$3,812.76

<b>XANAX</b>	<b>2008</b>
--------------	-------------

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1285681528	573	0	573	85	\$6,448.24
0040246*	452	4	448	189	\$5,080.71
1154379972	429	0	429	64	\$5,135.93
1356564371	383	0	383	77	\$3,914.04
1043211303	350	0	350	54	\$3,432.50
1396709457	331	0	331	50	\$3,210.83
1417964875	325	0	325	72	\$4,302.75
1538173778	319	2	317	50	\$3,900.64
1265411078	311	0	311	45	\$2,793.25
1407806128	310	0	310	58	\$3,037.50

**ABILIFY 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861562555	844	844	0	133	\$281,852.93
1215964796	803	803	0	92	\$183,043.09
1841220290	801	801	0	127	\$299,268.10
1285681528	743	743	0	130	\$247,307.97
1699850305	625	625	0	51	\$113,151.61
1508946088	493	493	0	78	\$164,440.62
1821196700	438	438	0	68	\$147,343.09
1407806128	435	435	0	74	\$169,158.95
1073500690	404	404	0	75	\$144,978.43
1982787727*	393	393	0	71	\$173,978.68

**GEODON 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215964796	768	768	0	73	\$107,689.82
1952333437	530	530	0	93	\$128,290.60
1699850305	323	323	0	28	\$33,101.29
1538173778	247	247	0	27	\$91,628.46
1285681528	237	237	0	38	\$61,586.87
1003867888	198	198	0	17	\$47,371.79
1376586800	184	184	0	23	\$48,847.27
1407806128	170	170	0	18	\$57,830.36
1598765877	165	165	0	16	\$45,595.62
1033157557	163	163	0	28	\$52,949.92

**SEROQUEL 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1538173778	851	851	0	127	\$269,474.50
1023002508	780	780	0	106	\$180,155.37
1730239732	599	599	0	87	\$136,541.82
1356564371	518	518	0	83	\$144,756.41
1285681528	513	513	0	89	\$191,223.08
1407806128	477	477	0	61	\$127,897.10
1619099884	438	438	0	67	\$133,240.11
1699850305	417	417	0	31	\$41,221.60
1710915392	405	405	0	59	\$146,981.79
1982605762	376	376	0	79	\$89,422.33

**ZYPREXA 2009**

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1861559486	308	308	0	61	\$99,384.77
1730239732	282	282	0	76	\$80,194.94
1023002508	172	172	0	14	\$71,611.06
1043211303	138	138	0	23	\$93,518.67
1538173778	128	128	0	16	\$104,249.86
1356564371	121	121	0	20	\$67,529.49
1841220290	112	112	0	15	\$54,703.57
1225097843	110	110	0	12	\$66,931.53
1699850305	105	105	0	12	\$16,517.35
1013964279	104	104	0	9	\$47,236.09

## RISPERDAL

2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1376586800	1,358	590	768	381	\$202,778.27
1457315285 *	1,160	422	738	196	\$140,463.51
1841220290	901	284	617	194	\$119,934.05
1568424208	896	278	618	114	\$67,568.41
1215964796	862	205	657	120	\$55,766.22
1043284169 *	853	314	539	208	\$106,374.18
1407806128	817	253	564	179	\$93,358.01
1861562555	776	250	526	193	\$73,940.63
1285681528	718	258	460	143	\$86,998.18
1861559486	704	187	517	164	\$72,668.19

## OXYCONTIN

2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215934914	201	47	154	44	\$32,959.13
1376538488	181	109	72	23	\$64,698.58
1952479024 *	85	24	61	22	\$11,643.60
1144290313	85	7	78	7	\$14,738.16
1134191018	74	13	61	7	\$7,587.05
1679688626	74	53	21	7	\$25,447.12
1811975469	68	13	55	11	\$39,653.72
1487680195	67	46	21	17	\$15,588.91
1972653962	67	22	45	7	\$16,028.32
1386757708	64	28	36	12	\$18,000.21
1063437812	64	1	63	6	\$652.03
1568570398	64	27	37	7	\$16,709.52

## ROXICODONE

2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1215934914	156	2	154	36	\$15,695.31
1376538488	85	13	72	15	\$3,338.79
1144290313	78	0	78	5	\$10,312.86
1063437812	63	0	63	5	\$568.83
1952479024 *	63	2	61	18	\$3,190.56
1134191018	61	0	61	6	\$2,472.28
1124020615	56	0	56	8	\$1,288.71
1811975469	55	0	55	9	\$5,259.13
1184697435	55	0	55	8	\$3,385.68
1730197476	54	0	54	12	\$7,865.25
1437176005	54	12	42	7	\$5,270.50

## XANAX

2009

Provider Identifier	Total Prescriptions	Brand Prescriptions	Generic Prescriptions	Total Unique Members	Paid Amount
1285681528	915	0	915	96	\$10,011.70
1356564371	760	0	760	104	\$7,424.15
1154379972	657	0	657	81	\$7,400.49
1043211303	577	0	577	64	\$5,266.37
1518913540	554	67	487	64	\$9,261.15
1417964875	463	0	463	75	\$5,317.49
1407806128	448	0	448	61	\$4,032.49
1033389226	392	0	392	69	\$4,624.23
1265411078	390	0	390	50	\$3,487.88
1407906407	365	0	365	46	\$3,629.15



# Iowa Medicaid Top 10 Prescribers for CY 2010 and 2011

CY 2010 : Average Monthly Eligibles

406,280

<b>ABILIFY</b>	<b>2010</b>
----------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1841220290	740	740	0	139	\$286,032.09
1861562555	730	730	0	111	\$268,189.41
1285681528	539	539	0	92	\$212,265.90
1508946088	529	529	0	73	\$180,219.52
1699850305	519	519	0	54	\$101,302.34
1215964796	514	514	0	75	\$108,332.99
1003884107	508	508	0	88	\$118,013.61
1891777009	490	490	0	79	\$183,186.31
1073500690	479	479	0	81	\$188,728.80
1982787727 *	455	455	0	83	\$209,452.82

<b>GEODON</b>	<b>2010</b>
---------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1215964796	649	649	0	55	\$85,085.62
1952333437	447	447	0	86	\$111,685.61
1699850305	321	321	0	40	\$36,893.69
1891777009	212	212	0	28	\$44,057.81
1003867888	208	208	0	20	\$58,940.14
1407806128	203	203	0	22	\$68,397.07
1285681528	175	175	0	32	\$57,650.92
1538173778	169	169	0	17	\$76,282.51
1841220290	163	163	0	25	\$43,526.38
1598765877	162	162	0	20	\$54,299.44

<b>SEROQUEL</b>	<b>2010</b>
-----------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1538173778	587	587	0	92	\$248,990.85
1023002508	584	584	0	95	\$156,464.12
1730239732	525	525	0	77	\$139,168.61
1699850305	523	523	0	41	\$65,488.93
1356564371	472	472	0	64	\$150,865.59
1619099884	465	465	0	58	\$157,840.93
1598714362	426	426	0	44	\$120,846.17
1629042288 *	421	421	0	66	\$78,958.84
1912991340	417	417	0	64	\$78,969.58
1700806262	412	412	0	103	\$45,583.17

<b>ZYPREXA</b>	<b>2010</b>
----------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1730239732	269	269	0	62	\$90,675.66
1861559486	244	244	0	57	\$90,241.51
1699850305	171	171	0	15	\$30,793.54
1023002508	168	168	0	13	\$75,295.67
1043211303	158	158	0	24	\$119,486.55
1285697722	146	146	0	20	\$86,738.71
1407806128	132	132	0	16	\$70,583.41
1538173778	132	132	0	12	\$135,858.42
1215964796	115	115	0	9	\$23,623.44
1225097843	112	112	0	11	\$80,891.36

\* 2/2012 - not currently enrolled individually  
in Iowa Medicaid

<b>RISPERDAL</b>	<b>2010</b>
------------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1013960566	1,205	11	1,194	209	\$29,066.49
1861562555	939	0	939	158	\$17,471.19
1457315285 *	893	59	834	114	\$39,049.82
1407806128	855	25	830	124	\$20,489.05
1861559486	826	0	826	127	\$14,739.43
1285681528	792	0	792	117	\$17,582.46
1841220290	771	14	757	133	\$22,516.52
1598714362	711	12	699	123	\$15,807.30
1912991340	673	19	654	122	\$16,360.28
1215964796	665	0	665	78	\$7,958.76

<b>OXYCONTIN</b>	<b>2010</b>
------------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1215934914	326	39	287	72	\$28,017.48
1295830115	215	37	178	51	\$29,482.17
1730319575	202	20	182	54	\$14,996.48
1629079280	152	4	148	38	\$6,860.70
1730197476	107	4	103	16	\$10,417.84
1538156138	92	0	92	15	\$2,761.65
1144290313	88	15	73	4	\$26,161.04
1487680195	72	42	30	17	\$13,473.08
1073667606	70	2	68	10	\$2,051.72
1790754695	68	26	42	12	\$44,050.11

<b>ROXICODONE</b>	<b>2010</b>
-------------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1295830115	29	29	0	19	\$136.58
1376538488	7	7	0	4	\$124.07
1437176005	7	7	0	1	\$2,084.61
1952459463 *	4	4	0	1	\$1,215.16
1730319575	3	3	0	1	\$686.04
1659590735	3	3	0	1	\$144.02
1407906407	2	2	0	1	\$170.50
1215934914	2	2	0	2	\$457.36
1609836600	2	2	0	1	\$447.34
1740500099 *	2	2	0	1	\$8.04
1912027608	2	2	0	2	\$37.68
1528227055	2	2	0	2	\$10.26

<b>XANAX</b>	<b>2010</b>
--------------	-------------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1285681528	1,117	0	1,117	143	\$9,096.59
1356564371	896	0	896	111	\$6,835.09
1154379972	738	0	738	92	\$5,623.07
1043211303	626	0	626	73	\$3,953.97
1225097843	610	0	610	103	\$4,059.75
1407806128	598	0	598	91	\$3,781.37
1518913540	568	75	493	56	\$6,057.14
1417964875	510	0	510	62	\$4,055.58
1699734129	455	5	450	64	\$3,390.56
1538156138	455	10	445	81	\$6,044.57

**ABILIFY 2011**

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1891777009	819	819	0	95	\$367,870.47
1841220290	700	700	0	106	\$323,501.98
1861562555	613	613	0	111	\$271,332.19
1003884107	589	589	0	104	\$182,789.52
1508946088	580	580	0	83	\$213,136.21
1922144088	484	484	0	83	\$158,682.42
1215964796	471	471	0	70	\$118,414.30
1073500690	467	467	0	73	\$200,913.51
1982787727 *	465	465	0	74	\$231,454.97
1619280625 *	410	410	0	77	\$185,175.66

**GEODON 2011**

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1952333437	531	531	0	103	\$130,211.82
1215964796	339	339	0	33	\$46,915.24
1891777009	309	309	0	28	\$96,406.07
1285681528	197	197	0	26	\$65,704.33
1003867888	192	192	0	18	\$58,499.05
1598714362	185	185	0	32	\$45,133.46
1295927291	159	159	0	18	\$47,086.67
1841220290	151	151	0	19	\$43,226.59
1023109865	148	148	0	31	\$49,779.31
1184722910	128	128	0	10	\$45,422.65

**SEROQUEL 2011**

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1912991340	532	532	0	96	\$113,261.16
1982605762	512	512	0	88	\$149,865.77
1598714362	494	494	0	52	\$151,627.56
1285681528	477	477	0	61	\$175,836.45
1023002508	440	440	0	90	\$122,661.36
1043211303	424	424	0	53	\$206,134.49
1023109865	417	417	0	73	\$114,468.56
1730239732	401	401	0	64	\$103,826.97
1356564371	385	385	0	68	\$119,931.92
1013964634	357	357	0	38	\$162,963.83

**ZYPREXA 2011**

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1861559486	249	247	2	48	\$117,510.84
1730239732	212	210	2	60	\$84,379.40
1043211303	206	206	0	36	\$189,284.47
1982605762	152	152	0	31	\$66,936.09
1841220290	137	137	0	15	\$98,243.60
1407806128	110	110	0	13	\$70,280.49
1225097843	107	107	0	12	\$97,171.06
1356321921	98	98	0	16	\$71,014.93
1285697722	95	95	0	11	\$79,864.21
1023109865	89	89	0	13	\$80,645.58
1598786097	89	88	1	22	\$40,943.09

## RISPERDAL

2011

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1013960566	1,166	8	1,158	215	\$21,413.42
1861562555	918	0	918	168	\$13,799.45
1598714362	889	22	867	131	\$19,368.89
1407806128	868	13	855	133	\$14,309.57
1285681528	845	0	845	113	\$15,071.40
1891777009	838	8	830	112	\$23,230.78
1841220290	833	10	823	117	\$15,876.63
1912991340	832	15	817	148	\$13,399.61
1861559486	808	0	808	123	\$11,031.77
1215964796	710	0	710	87	\$6,032.37

## OXYCONTIN

2011

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1295830115	611	81	530	90	\$64,137.28
1629079280	409	18	391	72	\$27,070.68
1215934914	367	36	331	91	\$25,136.71
1134397565	348	19	329	102	\$28,461.22
1730319575	332	43	289	97	\$26,167.08
1538157383	106	8	98	7	\$6,988.03
1730197476	99	2	97	14	\$6,302.09
1144290313	86	12	74	4	\$36,914.17
1972653962	79	27	52	6	\$18,580.24
1487680195	77	28	49	14	\$14,004.79

## ROXICODONE

2011

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1295830115	140	140	0	43	\$853.40
1538368170	6	6	0	1	\$24.41
1285607507	6	6	0	1	\$24.48
1952459463 *	6	6	0	1	\$1,907.66
1609861749	5	5	0	1	\$22.65
1043206741 *	3	3	0	2	\$17.16
1740500099 *	2	2	0	2	\$8.39
1548290182	2	2	0	1	\$58.04
1174759740 *	2	2	0	1	\$8.46
1578573846	1	1	0	1	\$156.48
1467652537	1	1	0	1	\$3.74
1215934914	1	1	0	1	\$239.95
1861462350	1	1	0	1	\$17.72
1003911686	1	1	0	1	\$10.17
1184645426	1	1	0	1	\$3.93
1942296876 *	1	1	0	1	\$5.72
1457346546	1	1	0	1	\$5.72
1558356642	1	1	0	1	\$4.23
1285604728	1	1	0	1	\$40.32
1528057387	1	1	0	1	\$69.11
1194794578	1	1	0	1	\$17.51
1659590735	1	1	0	1	\$43.54
1053631317 *	1	1	0	1	\$4.23
1710917026	1	1	0	1	\$95.80
1194773689	1	1	0	1	\$5.47
1881689636	1	1	0	1	\$3.64

XANAX	2011
-------	------

Provider Id	Total Prescriptions	Brand Rx	Generic Rx	Unique Members	Paid Amount
1285681528	1,282	0	1,282	174	\$10,412.72
1154379972	848	0	848	90	\$6,354.98
1225097843	792	1	791	119	\$5,490.59
1356564371	689	0	689	95	\$5,410.81
1043211303	652	0	652	75	\$3,947.05
1407806128	601	0	601	86	\$3,709.99
1518913540	525	0	525	76	\$2,830.68
1699734129	514	0	514	64	\$3,765.87
1457330474	481	0	481	62	\$2,579.87
1366573503	469	0	469	78	\$2,673.70